A novel method for the preparation of stavudine polymorphic form I and form II is described. 5′-acetate-2′3′-diacetyl-5-methyluridine is reacted with catalytic amounts of sodium methoxide in a C1-C4 alcoholic solvent resulting in crude stavudine form II. Crude stavudine form II can be converted into polymorphic stavudine form I by slurry at reflux in isopropanol without isolating or purifying the crude stavudine form II.

A novel method for the preparation of stavudine polymorphic form I and form II is described. 5'-acetate-2',3'-diacetyl-5-methyluridine is reacted with catalytic amounts of sodium methoxide in a C1-C4 alcoholic solvent, resulting in crude stavudine form II. Crude stavudine form II can be converted into polymorphic stavudine form I by slurry at reflux in isopropanol, without isolating or purifying the crude stavudine form II.

Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors viz. Zidovudine Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients.It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.(From US7700576 B2)

The present invention provides a method for preparing pure Stavudine having purity more than 99.5% comprises: i) Converting 3′5′-anhydrothymidine to crude Stavudine ii) Converting crude Stavudine to stable solvates of Stavudine iii) Desolvation of the solvates to give pure Stavudine. The present invention also disclosed novel solvates of Stavudine and conversion of novel Stavudine solvates to Stavudine.